Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice

Vanessa Hull; Yan Wang; Travis Burns; Sheng Zhang; Sarah Sternbach; Jennifer McDonough; Fuzheng Guo; David Pleasure

doi:10.1002/ana.25674

Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice

Vanessa Hull, Yan Wang, Travis Burns, Sheng Zhang, Sarah Sternbach, Jennifer McDonough, Fuzheng Guo, David Pleasure

Neurology

Research output: Contribution to journal › Article

Abstract

Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480–485.

Original language	English (US)
Pages (from-to)	480-485
Number of pages	6
Journal	Annals of Neurology
Volume	87
Issue number	3
DOIs	https://doi.org/10.1002/ana.25674
State	Published - Mar 1 2020

Fingerprint

ASJC Scopus subject areas

Neurology
Clinical Neurology

Cite this

Hull, V., Wang, Y., Burns, T., Zhang, S., Sternbach, S., McDonough, J., Guo, F., & Pleasure, D. (2020). Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice. Annals of Neurology, 87(3), 480-485. https://doi.org/10.1002/ana.25674

@article{b55eb52b393043739eb8342e005dcdfe,

title = "Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice",

abstract = "Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480–485.",

author = "Vanessa Hull and Yan Wang and Travis Burns and Sheng Zhang and Sarah Sternbach and Jennifer McDonough and Fuzheng Guo and David Pleasure",

year = "2020",

month = mar

day = "1",

doi = "10.1002/ana.25674",

language = "English (US)",

volume = "87",

pages = "480--485",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice

AU - Hull, Vanessa

AU - Wang, Yan

AU - Burns, Travis

AU - Zhang, Sheng

AU - Sternbach, Sarah

AU - McDonough, Jennifer

AU - Guo, Fuzheng

AU - Pleasure, David

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480–485.

AB - Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480–485.

UR - http://www.scopus.com/inward/record.url?scp=85078670741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078670741&partnerID=8YFLogxK

U2 - 10.1002/ana.25674

DO - 10.1002/ana.25674

M3 - Article

C2 - 31925837

AN - SCOPUS:85078670741

VL - 87

SP - 480

EP - 485

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -

Access to Document

10.1002/ana.25674